Technical Analysis for IMGN - ImmunoGen, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
3.17 | -0.94% | -0.03 |
IMGN closed down 0.94 percent on Friday, September 13, 2019, on 82 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Sep 27
*** please verify all earnings dates ***| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical IMGN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | -0.94% | |
| Upper Bollinger Band Walk | Strength | -0.94% | |
| Above Upper BB | Strength | -0.94% | |
| Overbought Stochastic | Strength | -0.94% | |
| Upper Bollinger Band Touch | Strength | -0.94% | |
| Expansion Breakout | Bullish Swing Setup | -1.86% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer NHL Amgen Immunogen Its Its Products Metastatic Small Cell Lung Cancer
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer NHL Amgen Immunogen Its Its Products Metastatic Small Cell Lung Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more IMGN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 9.84 |
| 52 Week Low | 1.76 |
| Average Volume | 1,838,470 |
| 200-Day Moving Average | 3.3295 |
| 50-Day Moving Average | 2.598 |
| 20-Day Moving Average | 2.799 |
| 10-Day Moving Average | 2.937 |
| Average True Range | 0.1656 |
| ADX | 31.77 |
| +DI | 30.0095 |
| -DI | 9.3203 |
| Chandelier Exit (Long, 3 ATRs ) | 2.7832 |
| Chandelier Exit (Short, 3 ATRs ) | 2.9868 |
| Upper Bollinger Band | 3.2378 |
| Lower Bollinger Band | 2.3602 |
| Percent B (%b) | 0.92 |
| BandWidth | 31.354055 |
| MACD Line | 0.1539 |
| MACD Signal Line | 0.1079 |
| MACD Histogram | 0.046 |
| Fundamentals | Value |
|---|---|
| Market Cap | 284.02 Million |
| Num Shares | 89.6 Million |
| EPS | -1.22 |
| Price-to-Earnings (P/E) Ratio | -2.60 |
| Price-to-Sales | 5.58 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.41 | ||||
| Resistance 3 (R3) | 3.42 | 3.35 | 3.37 | ||
| Resistance 2 (R2) | 3.35 | 3.29 | 3.35 | 3.36 | |
| Resistance 1 (R1) | 3.26 | 3.25 | 3.23 | 3.25 | 3.34 |
| Pivot Point | 3.19 | 3.19 | 3.17 | 3.19 | 3.19 |
| Support 1 (S1) | 3.10 | 3.13 | 3.07 | 3.09 | 3.00 |
| Support 2 (S2) | 3.03 | 3.09 | 3.03 | 2.98 | |
| Support 3 (S3) | 2.94 | 3.03 | 2.97 | ||
| Support 4 (S4) | 2.93 |
